Target intelligence / Profile preview

Antibiotic therapies

Molecular classification
Therapeutic Class, Pharmacological Group
01

Overview

Antibiotic therapies refer to a diverse range of medicinal compounds used to treat infections caused by bacteria by either killing the microorganisms or inhibiting their growth. Unlike specific molecular targets like receptors or enzymes, 'Antibiotic therapies' represents a broad therapeutic category that acts upon various bacterial structures, such as the peptidoglycan cell wall or the bacterial ribosome, which are distinct from human cellular components (NIH, 2023). These therapies are vital for managing conditions ranging from simple skin infections to complex systemic issues like sepsis (WHO, 2023). The clinical utility of these therapies is increasingly threatened by the emergence of antimicrobial resistance, where bacteria develop genetic mutations or acquire resistance genes to survive drug exposure (PubMed, 2022). Consequently, while essential for modern medicine, the use of these therapies requires careful stewardship to maintain efficacy and minimize side effects like gastrointestinal distress or severe allergic reactions.

Other names
AntimicrobialsAntibacterial agentsAntibioticsAntibiotic treatment
02

Mechanism of action

Antibiotic therapies function by targeting biochemical processes unique to bacteria. Mechanisms include the inhibition of cell wall synthesis (e.g., beta-lactams), interference with protein synthesis at the 30S or 50S ribosomal subunits (e.g., aminoglycosides, macrolides), inhibition of DNA replication via topoisomerase interference (e.g., fluoroquinolones), and disruption of folate metabolism (e.g., sulfonamides) (StatPearls, 2023; Merck Manual, 2022).

03

Biological functions

Bactericidal activityBacteriostatic activityInhibition of bacterial cell wall synthesisInhibition of bacterial protein synthesisInhibition of bacterial nucleic acid replication
04

Disease associations

InfectionBacterial infectionSepsisPneumoniaUrinary tract infectionMeningitis
05

Safety considerations

Antimicrobial resistance (AMR)Hypersensitivity and anaphylaxisClostridioides difficile-associated diarrheaNephrotoxicityOtotoxicityMicrobiome dysbiosis
06

Interacting drugs

Penicillins

6 more in the full profile.

07

Biomarkers

Minimum inhibitory concentration (MIC)ProcalcitoninC-reactive protein (CRP)Pathogen identification via PCRAntibiotic susceptibility testing (AST)

Beyond the preview

Go deeper on Antibiotic therapies.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antibiotic therapies.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call